Coherus Oncology (CHRS) Projected to Release Quarterly Earnings on Wednesday

Coherus Oncology (NASDAQ:CHRS) is expected to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.1150) per share and revenue of $14.4060 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Coherus Oncology (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $12.31 million for the quarter, compared to analyst estimates of $14.22 million. Coherus Oncology had a net margin of 397.30% and a negative return on equity of 198.90%. On average, analysts expect Coherus Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus Oncology Price Performance

Shares of CHRS opened at $1.44 on Tuesday. Coherus Oncology has a fifty-two week low of $0.81 and a fifty-two week high of $2.62. The firm’s 50-day simple moving average is $1.48 and its two-hundred day simple moving average is $1.67. The stock has a market cap of $222.12 million, a PE ratio of 0.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.52 and a current ratio of 1.56.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CHRS. Guggenheim began coverage on Coherus Oncology in a research report on Monday, May 11th. They issued a “buy” rating and a $12.00 price target on the stock. Weiss Ratings raised Coherus Oncology from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Coherus Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $8.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. grew its holdings in shares of Coherus Oncology by 45.6% during the fourth quarter. Invesco Ltd. now owns 380,033 shares of the biotechnology company’s stock valued at $540,000 after buying an additional 119,041 shares during the last quarter. XTX Topco Ltd raised its holdings in Coherus Oncology by 71.6% in the 4th quarter. XTX Topco Ltd now owns 166,797 shares of the biotechnology company’s stock worth $237,000 after acquiring an additional 69,621 shares during the last quarter. Millennium Management LLC purchased a new position in Coherus Oncology in the 4th quarter worth approximately $938,000. Bridgeway Capital Management LLC lifted its position in Coherus Oncology by 72.9% in the 4th quarter. Bridgeway Capital Management LLC now owns 441,000 shares of the biotechnology company’s stock valued at $626,000 after acquiring an additional 186,000 shares in the last quarter. Finally, Blair William & Co. IL purchased a new stake in Coherus Oncology during the 4th quarter valued at $27,000. Institutional investors own 72.82% of the company’s stock.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.